Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALL.

Blood Adv · 2024 · PMC11176965 · PMID 38598725

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Other genes previously involved in the pathophysiology and CNS infiltration in E2A-PBX1 + /preBCR + as Lck , Zap70 , and Cd79a , 13 , 15 , 29 showed a trend for decreased expression under the treatment with BTKi alone or in combination with dasatinib ( Figure 5 B).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.